Bicyclic fused pyrazole derivatives for the treatment of RSV
Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.
1. A method of inhibiting RSV, comprising administering to a patient in need thereof, an effective amount of a compound of Formula 1b:
or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof, wherein:
R 0 is a monocyclic or bicyclic heteroaryl-alkyl having at least three carbon atoms and to three heteroatoms selected from the group consisting of O, S, and N, wherein said heteroaryl is substituted with Cl, F, or methoxy;
R 1 and R b together form a double bond;
R 2 is phenyl-alkyl, wherein the phenyl is optionally substituted with methoxy;
R 3 is a monocyclic or bicyclic heteroaryl having one to three heteroatoms selected from the group consisting of O, S, and N, wherein the heteroaryl is optionally substituted with alkoxy, alkyl, oxycycloalkyl, Cl, or F;
R 4 and R 5 together form a carbonyl;
R 6 and R 8 together form a double bond;
R 7 is alkyl or aryl optionally substituted with —R c or —OR c ; and
R a is selected from the group consisting of —R c , —OR c , —N(R c ) 2 , —SR c , —SO 2 R c , —SO 2 N(R c ) 2 ; —C(O)R c , OC(O)R c , —COOR c , —C(O)N(R c ) 2 , —OC(O)N(R c ) 2 , —N(R c )C(O), —N(R c )C(O)N(R c ) 2 , —F, —Cl, —Br, —I, —CN, and —NO 2 ;
wherein R c is selected from the group consisting of hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, a monocyclic or bicyclic heterocyclyl having from two to eight carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N, C 6-12 aryl, a monocyclic or bicyclic heteroaryl having from three to twelve carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N, C 1-8 alkyl-C 3-8 cycloalkyl, a monocyclic or bicyclic heterocyclyl-alkyl having from three to sixteen carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N, C 1-8 alkyl-C 6-12 aryl, and a monocyclic or bicyclic heteroaryl-alkyl having from four to twenty carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N.
2. The method according to claim 1 , wherein R 7 is C 6 aryl.
3. The method according to claim 1 , wherein R 7 has the formula:
4. The method according to claim 1 , wherein R 7 has the formula:
5. The method according to claim 1 , wherein R 3 is a monocyclic or bicyclic heteroaryl having from three to twelve carbon atoms.
6. The method according to claim 1 , wherein R a is hydrogen.
7. The method according to claim 1 , wherein R 7 is C 1-8 alkyl.
8. The method according to claim 1 , wherein R 7 is methyl.
9. The method according to claim 1 , wherein R 2 is an unsubstituted phenyl-alkyl.
10. The method according to claim 1 , wherein R 0 is CH 2 -heteroaryl.
11. The method according to claim 1 , wherein R 0 is CH 2 -furan-2-yl.
12. The method according to claim 1 , wherein R 3 has the formula:
13. The method according to claim 1 , wherein R 3 has the formula:
14. A method of treating an RSV infection, comprising administering to a patient in need thereof an effective amount of a compound of Formula 1b:
or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof, wherein:
R 0 is a monocyclic or bicyclic heteroaryl-alkyl having at least three carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N, wherein said heteroaryl is substituted with Cl, F, or methoxy,
R 1 and R b together form a double bond;
R 2 is a phenyl-alkyl, wherein the phenyl is optionally substituted with methoxy;
R 3 is a monocyclic or bicyclic heteroaryl having one to three heteroatoms selected from the group consisting of O, S, and N, wherein the heteroaryl is optionally substituted with alkoxy, alkyl, oxycycloalkyl, Cl, or F;
R 4 and R 5 together form a carbonyl;
R 6 and W together form a double bond;
R 7 is alkyl or aryl optionally substituted with —R c or —OR c ; and
R a is selected from the group consisting of —R c , —OR c ′, —N(R c ) 2 , —SR c , —SO 2 R c , —SO 2 N(R c ) 2 —C(O)R c , OC(O)R c , —COOR c , —C(O)N(R c ) 2 , —OC(O)N(R c ) 2 , —N(R c )C(O), —N(R c )C(O)N(R c ) 2 , —F, —Cl, —Br, —I, —CN, and —NO 2 ;
wherein R c is selected from the group consisting of hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, a monocyclic or bicyclic heterocyclyl having from two to eight carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N, C 6-12 aryl, a monocyclic or bicyclic heteroaryl having from three to twelve carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N, C 1-8 alkyl-C 3-8 cycloalkyl, a monocyclic or bicyclic heterocyclyl-alkyl having from three to sixteen carbon atoms and one to three heteroatoms selected from the group consisting of 0, S, and N, C 1-8 alkyl-C 6-12 aryl, and a monocyclic or bicyclic heteroaryl-alkyl having from four to twenty carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N.
15. The method of treating an RSV infection according to claim 14 wherein the compound is administered via a route of administration selected from the group consisting of buccal, oral, intravenous, inhalation, intradermal, intramuscular, topical, subcutaneous, rectal, vaginal, parenteral, pulmonary, intranasal, and ophthalmic.
16. A compound of Formula 1b:
or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof, wherein:
R 0 is a monocyclic or bicyclic heteroaryl-alkyl having at least three carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N, wherein said heteroaryl is substituted with Cl, F, or methoxy,
R 1 and R b together form a double bond;
R 2 is a phenyl-alkyl, wherein the phenyl is optionally substituted with methoxy;
R 3 is a monocyclic or bicyclic heteroaryl having one to three heteroatoms selected from the group consisting of O, S, and N, wherein the heteroaryl is optionally substituted with alkoxy, alkyl, oxycycloalkyl, Cl, or F;
R 4 and R 5 together form a carbonyl;
R 6 and W together form a double bond;
R 7 is alkyl or aryl optionally substituted with —R c or —OR c ; and
R a is selected from the group consisting of —R c , —OR c ′, —N(R c ) 2 , —SR c , —SO 2 R c , —SO 2 N(R c ) 2 —C(O)R c , OC(O)R c , —COOR c , —C(O)N(R c ) 2 , —OC(O)N(R c ) 2 , —N(R c )C(O), —N(R c )C(O)N(R c ) 2 , —F, —Cl, —Br, —I, —CN, and —NO 2 ;
wherein R c is selected from the group consisting of hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, a monocyclic or bicyclic heterocyclyl having from two to eight carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N, C 6-12 aryl, a monocyclic or bicyclic heteroaryl having from three to twelve carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N, C 1-8 alkyl-C 3-8 cycloalkyl, a monocyclic or bicyclic heterocyclyl-alkyl having from three to sixteen carbon atoms and one to three heteroatoms selected from the group consisting of 0, S, and N, C 1-8 alkyl-C 6-12 aryl, and a monocyclic or bicyclic heteroaryl-alkyl having from four to twenty carbon atoms and one to three heteroatoms selected from the group consisting of O, S, and N.
17. The compound according to claim 16 wherein the compound is selected from the group consisting of:
18. A pharmaceutical composition comprising the compound of claim 16 and a pharmaceutically acceptable carrier, vehicle, or excipient.
19. The pharmaceutical composition according to claim 18 wherein the compound is selected from the group consisting of: